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In an era of reduced peer-reviewed grant funding, performing academic bone oncology-related research
has become increasingly challenging. Over the last 10 years we have held an annual meeting to bring
together clinicians, clinician/scientists and basic biomedical researchers interested in the effects of cancer
and its treatment on skeletal tissues. In the past these “Bone and the Oncologist New Updates Conference
(BONUS)” meetings have served as critical catalyst for initiating productive research collaborations be-
tween attendees. The 2015 BONUS meeting format focused on potential key research themes that could
form the basis of a coordinated national research strategy to tackle unmet clinical and research needs
related to complications associated with cancer metastasis to bone. The three themes planned for dis-
cussion were: Is bone metastases-related pain the main issue facing patients? Are there new therapeutic
targets for patients with bone metastases? How do we more ﬁrmly link basic science with clinical
practice? We present a summary of lectures and commentaries from the attendees to serve as an ex-
ample that other similarly motivated groups can model and share their experiences. It is our hope that
these presentations will result in comments, feedback and suggestions from all those researchers in-
terested in this important area.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over the last two decades, there has been a substantial increase in
our understanding of the underlying biology of bone metastasis as
well as the development and widespread incorporation of inhibitors
of osteoclast function, namely bisphosphonates and denosumab, into
clinical practice [1–3]. However, more recently there has been an
international fall in peer-reviewed grant funding [4]. This trend is
also clearly evident in the declining grant support provided by theGmbH. This is an open access art
cology, The Ottawa Hospital
).three Canadian federal funding agencies (Canadian Institutes of
Health Research (CIHR), Natural Sciences and Engineering Research
Council of Canada (NSERC) and Social Sciences and Humanities Re-
search Council (SSHRC) [4]. This has led to increased challenges in
performing academic bone metastasis research. The “Bone and the
Oncologist New Updates” (BONUS) meeting is an annual Canadian
multidisciplinary conference on the interaction of bone and cancer
biology [5,6]. The focus of the 2015 BONUS Conference (16 and 17
April 2015) was to discuss potential key research themes that could
form the basis for a coordinated national research strategy to tackle
unmet clinical and research needs related to complications asso-
ciated with cancer metastasis to bone.
This article captures a two-day programme of multidisciplinary
presentations, panel discussions and interactive dialogue on planningicle under the CC BY-NC-ND license
Table 1
Some unmet clinical and basic science questions.
Basic Science Clinical
Are osteoclasts the only stromal cell type that should be targeted
therapeutically?
What are the major issues affecting cancer patients with bone metastasis?
Are there new cancer/bone-stromal targets that should be developed? What do patients, nurses and clinicians feel are the most immediate concerns (bone pain,
mobility issues, and survival)?
What is our understanding of the biological mechanisms of pain associated
with bone metastasis?
Why do bisphosphonates and denosumab for metastatic bone cancers fail to prolong
overall survival?
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the data on bone pain management, expand our capacity to address
current and future development challenges, place strategies in the
context of the widespread use of bone-targeting agents and to act as
a forum for feedback and comments from other researchers inter-
ested in this ﬁeld.
1.1. Preliminary discussions leading to BONUS 2015
Prior to the BONUS 2015 meeting a preliminary meeting was
held in Montreal in November of 2014. The “working group” felt
that the development of speciﬁc research questions focused on
“bone metastasis” should be formulated from the starting point of
unmet clinical needs. In particular, the following issues were felt to
be of key importance: Understanding the biology associated with
the process of bone metastasis initiation and progression and
developing potential treatment strategies to improve outcome of
patients with bone metastases. Several questions were discussed
that are outlined in Table 1. There was also a strong feeling that
research initiatives should incorporate questions that cut across
the cancer care continuum from basic biomedical research to
clinical translation and patient outcomes. Based on the priorities
discussed during the preliminary meeting, the following themes
were selected for in-depth discussion at the 2015 BONUS meeting:
Is bone metastases-related pain the main issue facing patients?
Are there new therapeutic targets for patients with bone metas-
tases? How do we more ﬁrmly link basic science with clinical
practice? Each of these themes will be summarised below.
Theme 1. : Is bone metastases-related pain the main issue facing
patients?
This session consisted of presentations about metastasis-re-
lated bone pain from the perspectives of patient experience and
clinical care.
“What are the current limitations of bone-targeted agents in
relation to bone pain in patients with bone metastases?” Eitan
Amir, MD
While any malignancy may metastasise to bone, it is most
prevalent in advanced breast (70–80%), prostate (70–80%), thyroid
(60%), lung (10–50%) and renal cancers (30%) [7–11]. The con-
sequences of bone metastases include reduced survival, morbidity
and pain that negatively affect the patient's quality of life (QoL) as
well as skeletal-related events (SREs) [11,12]. Despite the fact that
randomized trials of bisphosphonates, and denosumab, have
shown reduced incidence of SREs, prolonged time to occurrence of
SREs and an improvement in pain control, clear improvements in
overall Quality of Life (QoL) have not been realized with their use.
Two trials comparing pamidronate to placebo showed that pa-
tients in the pamidronate arms experienced less pain; however,
there was no difference in the overall QoL [13]. Similarly, in the
randomized trial comparing denosumab to zoledronic acid, im-
provements in QoL were observed in both arms with denosumab
not showing consistently greater magnitude of improvement overthe entire trial period. Whether QoL improvements resulted from
the administration of bone targeted therapy or the concurrent
administration of systemic anti-cancer therapy is unclear espe-
cially as the placebo-controlled randomized trials of bispho-
sphonates did not show differences in QoL between arms [13–14]
Given that bone-targeting agents have not been found to affect
overall or progression-free survival and have known risks and
adverse effects, including rare but severe toxicities such as hypo-
calcaemia and osteonecrosis of the jaw (ONJ) [15–17], this lack of
improvement in QoL is disappointing. As we have likely reached
the limits of therapeutic osteoclast inhibition with bispho-
sphonates and denosumab there is increasing interest in the ef-
fects of other anti-cancer agents on the bone. For example, the use
of new treatments for prostate cancer such as abiraterone acetate,
enzalutamide and radium 223 have all shown decreased rates of
SREs as well as improvements in survival. As a result, there is a
need to develop better agents not only to reduce bone pain but to
also identify strategies to optimise the use of bone-targeted agents
as SREs become less common. As more effective cancer treatments
become available, it will be important to further explore optimal
dosing of bone-targeting agents in these patients.
“What do patients with bone metastases need?” Virginia Jarvis, RN
Virginia Jarvis, a nurse specialist in pain and palliative care, fol-
lowed up with a discussion of known as well as poorly understood
needs of patients with bone metastases in ambulatory and palliative
care. Pain assessment for patients with bone metastasis presents
unique problems as pain is often incidental in nature with high pain
scores with movement and minimal to zero pain scores at rest
making the standard 0–10 verbal scoring system an ineffective tool.
The Brief Pain Inventory was discussed as a pain assessment in-
strument that could best inform health care professionals to the
actual pain state and help guide the clinician to the choice of ap-
propriate treatments that may include interventional therapies that
go beyond the World Health Organisation Analgesic Ladder. Indeed,
in a large recently presented study, risk of SREs was correlated with
worsening pain scores on the Brief Pain Inventory [19]. The unmet
needs of patients include treatments such as physiotherapy, occu-
pational therapy and social work as pain effects mobility, activities of
daily living, the ability to drive and ﬁnancial decline. Following this
presentation there was extensive discussion around whether bone
pain was the major issue facing patients or reduced mobility. This
could be an important direction for future studies and requires fur-
ther evaluation.
“What are orthopaedic surgeons doing in 2015 for patients
with painful bone metastases?” Joel Werier, MD
Orthopaedic stabilisation of osseous metastatic lesions can provide
rapid and effective pain relief in patients presenting with signiﬁcant
bone destruction and impending or pathologic fracture. It is essential
to develop a collaborative relationship between engaged orthopaedic
surgeons and medical as well as radiation oncologists in order to fa-
cilitate multidisciplinary care of an individual patient. A clear under-
standing of life expectancy, patient expectations, and tumour biology
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orthopaedic interventions could be signiﬁcantly altered if it was evi-
dent that a patient had a very short prognosis. Tools to accurately
evaluate patient prognosis in this setting could be invaluable. Mini-
mally invasive techniques such as radiofrequency ablation, percuta-
neous cryoplasty, cementoplasty, and vertebroplasty can be effective in
patients who are poor surgical candidates or who have a speciﬁc le-
sion that can be addressed by these techniques. Surgical stabilization is
almost always supplemented with radiation to minimise tumour
progression and implant failure. A collaborative approach with or-
thopaedic surgical consideration can greatly aid in the palliation,
mobilisation, and quality of life of affected individuals. Basic and
translational researchers should be invited to collaborate with clin-
icians caring for patients with metastatic bone disease. For example –
is local delivery of biologics, incorportated into scaffods/cements used
to stabilise surgical defects a useful approach? In addition, in our
centre orthopaedic stabilization with tumour de-bulking is a unique
opportunity to provide good quality tumour specimens for basic sci-
ence and translational research investigating novel therapies.
“Study endpoints in trials of bone-targeted agents and radio-
therapy – should bone pain be a criteria?” Kris Denis MD and
Mark Clemons, MD
Traditionally, bisphosphonates have been evaluated in terms of
SRE prevention; however, its deﬁnition has changed with time. For
example, while older studies included hypercalcaemia as an SRE,
most subsequent trials do not take it into account. Second, clinical
trials often mandate bone surveys and isotope bone scans every
3 months, resulting in the detection of asymptomatic SREs. In-
cluding these asymptomatic events as endpoints makes it chal-
lenging to determine whether newer agents actually represent an
improvement in preventing what truly matters to patients:
symptomatic SREs [20–22]. Another factor limiting the use of SREs
as a meaningful endpoint is that bone pain per se is not considered
a SRE despite the fact that clearly impacts patient QoL and is tied
to the use of radiotherapy. Indeed, the conditions under which
radiotherapy has been indicated (and recorded as a SRE in pre-
vious trials) are not standardized. Indeed, a review of literature
and survey on QoL perception outcomes of radiation therapy for
bone metastasis has shown that the impact of metastatic disease
and radiotherapy extends beyond pain [23]. Looking beyond sim-
ple endpoint metrics, perhaps an alternative way to measure the
impact of bone metastases on patients is through a broader ex-
amination of QoL impact. The European Organisation for Research
and Treatment of Cancer (EORTC) Quality of Life Group Bone
Metastases Module (EORTC QLQ BM22) is a bone metastases-
speciﬁc instrument that measures the impact of bone metastases
on patients’ quality of life. It has been extensively validated in-
ternationally and is well-suited to use within clinical trials [24].
Conclusion 1: Given that pain/mobility remains a signiﬁcant issue
for many patients, the group felt the ﬁrst priority for future studies
should be to investigate the experience in patients with bone me-
tastatic cancer with regard to pain, mobility, fatigue, psychological
distress, reduced performance and treatment side-effects. It will only
be possible study the impact of all these issues in the individual
patient with a dedicated bone metastasis health-related QoL tool.
Theme 2. Are there new targets for patients with bone metastases?
The second session involved presentations discussing the
strategies and ideas in development of new treatment strategies
for patients with bone metastases.
“Better use of established agents?” mark Clemons, MD
One of the ways to improve therapeutic outcomes would be to
use current agents more effectively [25–26]. Given that patientswith bone-only metastatic disease may experience longer term
survival, and the risk of adverse events from bone-targeting agents
increases with cumulative exposure, the question around optimal
dose and dosing interval remains unanswered [26–28]. A survey of
physicians who treat patients with bone metastases from breast
cancer and metastatic castration-resistant prostate cancer showed
signiﬁcant variability in the use of bone-targeting agents, includ-
ing the choice and dosing interval [29]. A systematic review
evaluating de-escalated treatment (i.e. every 12 weeks) of breast
cancer patients with bone-targeted agents in comparison to cur-
rent standard practice of every 3–4 weeks showed a clear
knowledge gap with regard to establishing the clinical beneﬁts of
de-escalated bone targeted agent therapy in metastatic breast
cancer patients [24]. Similarly, a recent systematic review also
demonstrated that denosumab 12-weekly was as effective as
4-weekly dosing in patients with bone metastases from prostate
cancer (“in press”). Integration of these reduced frequencies of
bone-targeted agents into routine clinical practice could beneﬁt
both patients (reduced visits to the cancer centre for treatment
and less drug toxicity) and the health care system (lower drug
costs).
For many years it has been hoped that use of biochemical
endpoints, such as bone resorption markers, may offer a solution
to the challenge of using pain scores by offering a quantitative,
rather than qualitative, assessment of bone-targeting agent effect
on the bone in the presence of skeletal metastases. Retrospective
analyses of bisphosphonate trials suggest that early normalisation
(at 3 months) of urinary N-terminal telopeptide levels in patients
undergoing treatment with bisphosphonates are associated with a
signiﬁcantly reduced risk of a ﬁrst SRE, ﬁrst fracture, surgery to
bone, or death [30]. However, incorporation of these biomarkers of
bone turnover, pain scores and SREs to develop practical strategies
to improve the care of patients has to date been extremely chal-
lenging [31–33].
“Models for bone metastases” Christina Addison, PhD
There are a number of pre-clinical animal models to study
cancer metastasis to bone. Typically, approaches are employed
that include syngeneic, transgenic and xenograft models of bone
metastasis. Experimentally, the most frequent route of injection of
cancer cells is intracardiac (into left cardiac ventricle), which
permits seeding and colonisation of tumour cells in metaphyses of
the long bones. Intratibial (intraosseous) injection of tumour cells
directly into the marrow space is often used to examine tumour
stromal interactions during the growth of bone metastatic lesions.
Finally, vossicle models are emerging in which foetal human bone
is implanted subcutaneously into mice, followed by intra-cardiac
or local injection of human tumour cells that colonise the human
bone fragments and form metastases. Histological and im-
munhistochemical techniques are employed to study excised tis-
sues while increasingly, in vivo imaging modalities (optical ima-
ging systems (IVIS), radiography, μCT and MRI) have been used to
assess the growth of bone metastatic lesions and the effect on
bone resorption/destruction.
While these models have been very useful in delineating me-
chanisms that drive the colonisation and growth of cancer cells in
bone, they have not been interrogated sufﬁciently [33]. Hopefully
these models can be utilised further to identify novel therapeutic
targets and develop more effective treatment combinations that
could enhance overall survival.
“New targets” john Hilton, MD
A series of potential emerging agents may be helpful in ad-
dressing bone-only disease. Cabozantinib (XL184) is an orally
bioavailable tyrosine kinase inhibitor with potent activity against
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static prostate cancer, cabozantinib demonstrated signiﬁcant and
rapid effects on bone scan lesions as well as on markers of bone
formation and resorption, bone pain and narcotic use. In addition,
statistically signiﬁcant improvement in progression-free survival
was seen with cabozantinib compared with placebo. While the
subsequent larger registration study was negative in terms of
overall survival, it again showed important ﬁndings in metastatic
bone disease, including resolutions of metastases in bone scans
and reductions in bone turnover markers [34]. It is possible that
the observed clinical effects on bone are related to decreased
RANKL expression in osteoblastic cells and inhibition of osteo-
clastogenesis and PTHrP-stimulated bone resorption, thus pro-
viding a rationale for beneﬁcial skeletal observations while failing
to control progression of the malignancy. It is also possible that
cabozantinib should not be considered a bone-targeting agent
per se, but as an effective anti-tumour agent given its efﬁcacy in
metastatic renal cell cancer [35]. Given the effects of cabozantinib
on bone metastases in patients with castration resistant prostate
cancer it would be interesting to see whether or not combinations
with bisphosphonates or denosumab are synergistic or not.
“Radium 223 as a novel therapeutic for bone metastases” Urban
Emmenegger, MD
Radium 223 is a “calcium mimetic” alpha emitter that selec-
tively binds to areas of increased bone turnover such as bone
metastases. In patients with castration-resistant prostate cancer,
radium 223 signiﬁcantly improved overall survival as well as time
to ﬁrst symptomatic skeletal related event [36]. QoL was also seen
to be better with radium 223 versus placebo. Since radium 223 is
the ﬁrst bone-targeted agent with documented positive impact on
overall survival. As with cabozantinib, mentioned above, it is also
possible that as radium 223 delivers radiation to the bone me-
tastases itself it should also be considered an anticancer agent and
not just a bone-targeted agent. Results in other tumour types such
as breast cancer are eagerly awaited.
“Immune therapies for bone metastases” Guy Ungerechts, Md
Targeted infection of cancer using novel oncolytic viral thera-
pies via binding of tumour-speciﬁc surface receptors is an exciting
and promising ﬁeld. Therapy combining oncolytic virus with an
immune checkpoint blockade for immunovirotherapy can lead to
an immunomodulation and ultimately disease response. While
immunomodulation may prove to be extremely important for ef-
fective tumour control in the bone microenvironment, tumour-
speciﬁc receptors for bone metastatic lesions remain less well
characterized.
Theme 2 conclusion. : Despite over two decades of widespread
use of osteoclast-targeting agents such as bisphosphonates and
more recently denosumab these have had no discernible effect on
response rates, progression free or overall survival. Studies on
dosing intervals with osteoclast-targeting agents continue to show
that treatment can be safely de-escalated and studies are needed
to explore their role in the presence of increasingly effective anti-
cancer agents. However, clearly new targets are needed. Studies
will need to integrate basic science models into clinical practice so
that novel agents and their combinations can be more rapidly
evaluated in the laboratory before performing large, expensive
studies in patients.
Theme 3. How do we more ﬁrmly link basic science with clinical
practice?
It is evident that there has to be meaningful collaboration be-
tween basic science and clinical practice. In the ﬁnal session, bone
metastasis models and their limitations were discussed. Finally,clinicians presented information on future directions in the bone
metastasis research ﬁeld. It was hoped that this would provide
additional information for basic science collaboration.
“Animal models for bone cancer-induced pain” Svetlana V.
Komarova, PhD
One of the factors limiting research into the area of bone can-
cer-induced pain is the limited number of animal models where
treatment hypotheses can be tested. Dr Komarova presented data
on the behavioural pain phenotype in an experimental breast
cancer bone metastasis model and on the pain-relieving effects of
microenvironment-targeting adjuvant therapies. In a mouse
model, where immunocompetent mice were injected intra-tibialy
with murine mammary carcinoma cells or saline, breast cancer
bone metastasis was associated with gradual development of os-
teolysis, spontaneous limping and guarding of affected limbs, as
well as a signiﬁcant increase in the sensitivity to mechanical, heat
and cold stimuli [37]. Moreover, unilateral breast cancer bone
metastasis was found to drive hypersensitivity, bone remodelling
and sensory neuronal plasticity at sites distant from the tumour
area [38]. The anti-inﬂammatory and osteolysis-targeting drug
rapamycin reduced hypersensitivity to mechanical and thermal
stimuli in the cancer-bearing and contralateral limbs, while the
osteoclast-targeting drug pamidronate reduced thermal sensitivity
at the cancer-bearing and contralateral limbs. Thus, localised bone
cancer drives osteolysis, sensory hypersensitivity, and neuroplas-
ticity both locally and distantly from the primary lesion. Ultimately
mechanistic based therapeutics is essential to develop novel
agents for cancer induced bone pain.
Unfortunately, despite the promise of these models, there are
difﬁculties in translating these studies to patient experience. First,
while pain assessment in patients is generally done using vali-
dated questionnaires, such tools are not practical in animal stu-
dies. In contrast, quantitative sensory tests which assess the sen-
sitivity thresholds to mechanical and thermal stimuli can be used
in humans and animals, and were shown to be informative and
predictive in patients with neuropathic and musculoskeletal pain
[39–40], as well as chemotherapy-related pain in cancer patients
[41–42]. However, the validity of quantitative sensory tests in
providing measurable pain information in bone metastasis pa-
tients has been only assessed in a small number of patients [43],
making it impossible to translate pain-related conclusions ob-
tained in animal studies to patient care. In addition, the treatment
protocol in experimental animals commonly does not reﬂect the
usual treatment protocol in patients such as use of clinically re-
levant chemotherapy dosing schedules and time delay between
initiation of bone metastasis and development of symptoms which
will lead to treatment in patients. Thus, development of direct
correlates between measures used to quantify the disease pro-
gression in animal models and in patients will help in knowledge
translation from basic science studies to clinical care.
“Challenges of ex-vivo models for identifying new targets”
Christina Addison, PhD
A signiﬁcant limitation of the use of cell lines in breast cancer
bone metastasis related research has been the fact that so many cell
lines are from hormone receptor negative lines, when the vast ma-
jority of patients have hormone receptor positive disease. Dr. Addison
and her team have therefore established a programme in collabora-
tion with orthopaedic surgeons to obtain tumour tissue straight from
the operative room from patients undergoing surgery for bone me-
tastases complications. As a result, it is possible to isolate new bone
metastatic-derived cancer cell lines, to test drug combinations in
ex vivo bone metastatic tumour tissues and to develop patient de-
rived xenograft models. There remain challenges in translating these
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tative assays for tumour burden and ultimately evaluate response to
treatment in vivo and models that can better mimic to the human
in vivo phenotype.
“Bisphosphonates as adjuvant therapy for breast cancer and the
relevance of the low estrogen environment”Alexander Paterson, MD
Since bisphosphonates were found to beneﬁt patients with
bone metastases from breast cancer, trials of adjuvant bispho-
sphonates in operable primary breast cancer were set up in the
1990s and early 2000s, some using end-points appropriate for a
class of drugs whose dominant mode of action is in bone (e.g. bone
metastasis-free interval and overall survival [OS]), and others,
using traditional cancer trial endpoints (disease-free survival [DFS]
and OS). Prior to these trials there was substantial pre-clinical and
clinical evidence that bisphosphonates had anti-osteoclastic ac-
tions and there was some limited pre-clinical evidence of direct
cytotoxic anti-tumour effects [33]. Importantly, there was also
evidence in preclinical in-vitro and animal studies of the role of
the “vicious cycle” in promoting bone metastasis growth [44–45];
and it was known that tumour growth could be inhibited using
bisphosphonates [46].
Not surprisingly, DFS beneﬁts have been difﬁcult to demon-
strate in any single trial (except ABCSG-12). Adjuvant clinical trials
accrued breast cancer patients of all ages and these trials have not
demonstrated clear beneﬁts in the primary endpoints of DFS and
OS. However, protocol stipulated analysis by stratiﬁcation arms in
the three largest randomized trials (post- and pre-menopausal in
AZURE; or age450 versus o50 in NSABP and Royal Marsden
trials) revealed a signiﬁcant beneﬁt for DFS/OS in post-menopausal
women (AZURE) and for bone metastasis-free interval and OS in
women 450 (NSABP and Royal Marsden). Many clinical scientists
believe that a consistent observation like this across three large,
well-conducted independent trials is a powerful observation.
Furthermore, using traditional chemotherapy primary end-points
such as DFS (which includes second primaries, contra-lateral
breast cancer and loco-regional recurrences) for assessing a bone
drug is likely to miss a valuable clinical effect.
An individual patient-level meta-analysis of all adjuvant bi-
sphosphonate trials was proposed by the EBCTCG and this study
has now been published conﬁrming the validity of the observation
that bone-metastasis free survival and overall survival beneﬁts
occur in post-menopausal and older women receiving bispho-
sphonate therapy (either oral clodronate or intravenous amino-
bisphosphonates) [45]. The reason for this beneﬁt is not clear.
Suggestions have been proposed around the role of a “low estro-
gen environment”. Interactions between reproductive hormones,
tumour and bone cell biology, and marrow stem cells evolve
during the menopausal transition where estradiol and inhibin
dominate in the pre-menopausal woman, and activin and the TGF-
beta superfamily dominate as bone metabolism regulators in the
post-menopausal woman [46].2. Conclusion
Bone oncology requires a multi-disciplinary team approach and
a diverse arsenal of cancer therapeutics. The BONUS 2015 meeting
was structured to identify unanswered research questions and
unmet clinical needs that could form the basis for an integrated
team grant application, with the goal of positively impacting the
care of bone metastatic patients. This review summarizes the bone
oncology-related topics presented and discussed among the
meeting attendees. It is clear that many unsolved challenges and
knowledge gaps currently exist that are barriers to effectivetreatment of metastatic bone disease, which represent opportu-
nities for additional research by a multi-disciplinary team.Acknowledgements
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